Tuesday, February 09, 2021 10:10:43 AM
More content below
ProPhase Labs, Inc.
Tue, February 9, 2021, 8:30 AM
More content below
PRPH
-2.40%
Company Integrates Spectrum Solutions™ SDNA-1000 Saliva Collection System for Advanced, Simultaneous Multi-Viral Detection of Infections and Viral Mutations
GARDEN CITY, NY, Feb. 09, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, has begun new saliva-based, viral RT-PCR multiplex-testing as a laboratory developed test (LDT) classification. Emergency use authorization (EUA) applications have been filed and confirmed by the U.S. Food and Drug administration (FDA) for its two new testing methodologies. Testing integrates the Spectrum Solutions saliva self-collection system with a new, advanced multiplex qPCR platform for the simultaneous RNA detection of not only SARS-CoV-2 (COVID-19) but also COVID-19 viral mutations, as well as Influenza A, B, and more.
This new SDNA Viral™ saliva-based testing combo features pain-free self-collection, 100% in-device viral neutralization, removes the need for cold-chain storage of samples, and provides critical sample consistency for optimal accuracy. It additionally offers patients the most intuitive and safest sample collection process while delivering the most robust testing biomaterial for the detection of multiple viral infections or mutations in a single test.
Spectrum Solutions, innovative medical device manufacturer and industry leader in bio-sample collection devices, helped secure the FDA’s very first saliva-based testing EUA and continues to lead the charge in saliva-based molecular diagnostic solutions and research. This new, efficient, and cost-effective multi-viral testing product has been engineered to increase testing accuracy and overcome the challenges of limited samples and costly analysis.
This testing provides patients an immediate diagnostic advantage using a single saliva test to quickly detect and identify COVID-19, any of its 17+ current viral mutations, including those first reported in the United Kingdom and now found throughout the United States as well as Influenza A and B. With test processing already underway at both ProPhase New York and New Jersey CLIA certified lab locations, this new, innovative technology ensures optimal assay reliability, offers numerous diagnostic advantages over other testing applications, and delivers the capacity to process more than 60,000 tests per day.
“We are privileged to be working with Spectrum Solutions, one of the leading life-science companies in the world on innovative testing solutions for detecting dangerous viruses including COVID-19,” said Ted Karkus, CEO of ProPhase Labs. Mr. Karkus added: “This collection device and multiplex testing methodology deliver significant value to testing that other platforms have missed. Not only does our methodology identify the original COVID-19 virus, our assay also has the multiplex capability of identifying Covid-19 viral mutations. With the FDA deciding to limit its review of EUA submissions for COVID-19 laboratory developed tests, receiving confirmation of a formal review from the FDA device division is a great win for all of us. Our new state-of-the-art molecular diagnostic testing equipment from Thermo Fisher not only streamlines testing results but prepares us for additional testing capabilities moving forward.”
“Testing is the purposeful pursuit of understanding a disease and a window into each individual’s personalized response,” said Bill Phillips, Chief Operating Officer at Spectrum Solutions. Mr. Phillips added: "Without testing, patients and medical professionals would not be able to make informed decisions on the proper treatment path. We could not be more excited to partner with industry front-runner ProPhase Labs on the new Spectrum SDNA Viral testing solution. The industry needs more innovative testing collaborations like this, delivering real actionable insights, to help move us all forward."
This collaboration coupled with other technologies and innovations will continue to provide a wide range of laboratory testing services for the diagnosis, screening, and evaluation of additional diseases. For more information on the RT-PCR multiplex testing, competitive pricing and some of the industry’s fastest testing turnaround times, please contact us at 866-7LAB TEST (866-752-2837) or info@prophasedx.com
ABOUT SPECTRUM SOLUTIONS™, SPECTRUM DNA™
Headquartered in Salt Lake City, Utah, Spectrum Solutions and its medical device division, SpectrumDNA, focus their industry expertise on engineering innovative end-to-end solutions for clinical diagnostic projects and commercial product plans. A single-source solution provider for medical device development, manufacturing, custom packaging, kitting, and direct-to-consumer fulfillment. Their bio-sample collection devices, patented technologies, and dedicated client services deliver measurable process optimization, unprecedented efficiency, and unmatched global scalability. For more information, please visit spectrumsolution.com/SDNA.
About ProPhase Labs
ProPhase Labs (NASDAQ: PRPH) is a diversified medical science and technology company with deep experience with OTC consumer healthcare products and dietary supplements. The Company is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. This includes the development and marketing of dietary supplements under the TK Supplements® brand. The Company’s subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”), offers COVID-19 and other Respiratory Pathogen Panel (RPP) Molecular tests. The Company also continues to actively pursue strategic investments and acquisition opportunities for other companies, technologies, and products. For more information visit us at www.ProPhaseLabs.com.
Recent PRPH News
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 08/22/2024 10:07:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 09:17:31 PM
- ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event • GlobeNewswire Inc. • 08/19/2024 03:10:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:09:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:05:37 PM
- ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2024 • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
- ProPhase Labs Announces Collaboration with Forward Healthcare Consultants to Aid in the Commercialization of its Billion Dollar Potential BE-Smart Esophageal Cancer Test • GlobeNewswire Inc. • 08/13/2024 12:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/09/2024 08:30:25 PM
- PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14 • GlobeNewswire Inc. • 08/07/2024 12:00:00 PM
- ProPhase Labs Announces Update on Pharmaloz Manufacturing, Inc. Progress • GlobeNewswire Inc. • 07/11/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/20/2024 08:20:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:04:58 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/09/2024 09:08:47 PM
- ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated • GlobeNewswire Inc. • 05/09/2024 07:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:05:43 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/09/2024 12:00:38 PM
- ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. • GlobeNewswire Inc. • 05/09/2024 12:00:00 PM
- PROPHASE LABS INC. TO PRESENT FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 9 • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- ProPhase Labs Unveils Project ZenQ-AI • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024 • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2024 01:00:00 AM
- ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives • GlobeNewswire Inc. • 03/15/2024 12:00:00 PM
- PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024 • GlobeNewswire Inc. • 03/08/2024 01:00:00 PM
- ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM